Lerma Enrique, Mora Josefina
Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University, Barcelona, Spain.
Cancer. 2005 Dec 25;105(6):492-7. doi: 10.1002/cncr.21380.
Telomerase activity (TA) has been detected in most malignant neoplasms, including thyroid carcinomas. The authors studied the utility of TA detection as an ancillary tool to thyroid fine-needle aspiration (FNA) for patients with nonconclusive cytologic diagnoses.
Material obtained by FNA from palpable thyroid nodules in 167 consecutive patients was processed for conventional cytologic studies and simultaneously for TA study. Another 8 patients were excluded from TA because of the presence of lymphocytes. All patients with negative results cases were followed for > 1 year, and those who had tumors that were suspicious or positive by FNA or TA underwent resection for pathologic study of nodules. TA was analyzed by telomere repeat amplification protocol-polymerase chain reaction analysis.
After excluding 20 patients because of insufficient material for cytologic study, 120 patients had negative results for malignant cells in cytology material, and the remaining 27 patients had results that were either suspicious (n = 21 patients) or positive (n = 6 patients). Histopathologic confirmation was obtained in 23 patients, including 18 with suspicious cytology (1 with scanty material) and 5 with positive FNA. The histopathologic diagnoses were nodular hyperplasia in 5 patients, follicular adenoma in 3 patients, papillary carcinoma in 11 patients, follicular carcinoma in 1 patient, medullary carcinoma in 2 patients, and lymphoma in 1 patient. TA was detected in 6 of 18 histologically confirmed thyroid neoplasms (1 of 3 follicular adenomas, 3 of 11 papillary carcinomas, 0 of 1 follicular carcinoma, 1 of 2 medullary carcinomas, and 1 of 1 lymphoma), including 1 neoplasm with scanty atypical cells.
The detection of TA helped to confirm neoplasia in 6 of 23 suspicious thyroid nodules. Although it was less sensitive than FNA, TA specificity was 100% for neoplasia and 87.5% for malignancy. The sensitivity of thyroid FNA increased with the use of TA detection when cytology was nonconclusive for malignancy.
在包括甲状腺癌在内的大多数恶性肿瘤中都检测到了端粒酶活性(TA)。作者研究了TA检测作为甲状腺细针穿刺活检(FNA)辅助工具,用于细胞学诊断不明确患者的效用。
对167例连续患者可触及的甲状腺结节进行FNA取材,用于常规细胞学研究,并同时进行TA研究。另外8例因存在淋巴细胞而被排除在TA研究之外。所有结果为阴性的患者均随访超过1年,FNA或TA检查结果可疑或阳性的患者接受结节切除以进行病理研究。通过端粒重复序列扩增法-聚合酶链反应分析检测TA。
因细胞学研究材料不足排除20例患者后,120例患者的细胞学材料中恶性细胞结果为阴性,其余27例患者的结果可疑(21例患者)或阳性(6例患者)。23例患者获得了组织病理学确诊,包括18例细胞学可疑患者(1例材料不足)和5例FNA阳性患者。组织病理学诊断为结节性增生5例、滤泡性腺瘤3例、乳头状癌11例、滤泡癌1例、髓样癌2例和淋巴瘤1例。在18例经组织学确诊的甲状腺肿瘤中有6例检测到TA(3例滤泡性腺瘤中的1例、11例乳头状癌中的3例、1例滤泡癌中的0例、2例髓样癌中的1例和1例淋巴瘤中的1例),包括1例非典型细胞较少的肿瘤。
TA检测有助于确诊23例可疑甲状腺结节中的6例。虽然TA检测不如FNA敏感,但其对肿瘤的特异性为100%,对恶性肿瘤的特异性为87.5%。当细胞学对恶性肿瘤诊断不明确时,联合TA检测可提高甲状腺FNA的敏感性。